Tagged with IP

Taiwan In just 35 years, Taiwan has gone from having no biotechs on the TAIEX and Taiwan OTC stock exchanges to 124 listed firms with a combined market capitalization of more than USD 30 billion by 2020, as the below chart from the Carnegie Endowment for International Peace shows. In 2019,…

Global At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era, shared lessons from the COVID-19 pandemic experience, insights into the importance of building leadership skills, and using technology as an…

Greece Ipsen’s George Carystinos explains what brought him back to Greece for a first country manager position after a succession of global roles, how the company’s global specialty care transformation is playing out in the Greek market, and why he is optimistic about the impact that Ipsen’s portfolio can have in…

Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…

Egypt The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power its future growth as well as expanding its international footprint.   Biologics: A Big Leap Forward The company’s plan to…

Egypt As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here, three regional managers give their takes on what Egypt means to their companies, and their hopes for its future development.…

Middle East & Africa General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years – starting in the UAE and expanding into Saudi Arabia – and in so doing turned MEA into one of its growth centres. As the company plans to increase…

Egypt Bristol Myers Squibb’s Oscar Delgado outlines the firm’s successes in bringing innovative medicines to the Middle East and Africa in recent years, how its strategy plays out in an economically diverse region, why partnerships are of vital importance, and the ways in which BMS is participating in Egypt’s healthcare transformation.…

Asia-Pacific The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share purchase, China-based MGI Tech’s participation in Thailand’s genomics initiative and Boston Scientific’s expanded operations in Malaysia.   GSK invests SGD…

Gobal Thomas Schinecker is set to replace long-standing CEO, Severin Schwan, in the leadership shakeup Roche announced a few months ago. Schinecker is known for leading the company’s COVID-19 test kit efforts as the CEO of its diagnostics division, but he comes to the helm after an almost 20-year career at…

Ireland Recent announcements from Ipsen and AbbVie of multimillion Euro investments into Irish manufacturing plants underline the Celtic nation’s continuing attractiveness to pharma multinationals. While an upcoming hike in Ireland’s famously low corporate taxation rates could dampen investor enthusiasm, industry insiders are bullish on the country’s continuing attractiveness.   Banking on…

India As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality compliance issues. After Sun Pharma, Aurobindo and Zydus found themselves on the FDA’s radar earlier this year, two more Indian…